Poor
Not Aligned
Patient Risk:
High
Summary
Most claims are not supported by the provided Forteo (teriparatide) label text, and several statements are either incorrect relative to labeled contraindications/precautions or include non-label items (e.g., Prolia transition guidance, CTX monitoring, cost, patents, and overlap dosing). The supplied label text does not address denosumab (Prolia) transitions, rebound fracture timing, or related guidance.
Category Scores
Accurate Statements
Forteo (teriparatide) stimulates new bone formation on trabecular and cortical bone surfaces by preferentially stimulating osteoblastic activity over osteoclastic activity.
12.1 Mechanism of Action (pattern of exposure; once-daily teriparatide stimulates new bone formation on trabecular and cortical surfaces; preferential stimulation of osteoblastic activity).
Forteo is indicated for osteoporosis (postmenopausal women at high risk; men with primary or hypogonadal osteoporosis at high risk; men and women with glucocorticoid-associated osteoporosis at high risk).
1 INDICATIONS AND USAGE.
Forteo is administered subcutaneously once daily at 20 mcg per dose.
2.1 Recommended Dosage (20 mcg subcutaneously once a day).
Forteo should be used for more than 2 years during a patient's lifetime only if the patient remains at or has returned to having a high risk for fracture.
2.3 Recommended Treatment Duration (use >2 years only if still/returned to high risk for fracture).
Forteo is contraindicated in patients with hypersensitivity to teriparatide or excipients.
4 CONTRAINDICATIONS (hypersensitivity).
Avoid Forteo use in patients with metabolic bone diseases other than osteoporosis, including Paget's disease of the bone.
5.1 Osteosarcoma (avoid in metabolic bone diseases other than osteoporosis, including Paget's disease of the bone).
Avoid Forteo use in patients with prior external beam or implant radiation therapy involving the skeleton.
5.1 Osteosarcoma (avoid if prior external beam or implant radiation therapy involving the skeleton).
Avoid Forteo use in patients with bone metastases or a history of skeletal malignancies.
5.1 Osteosarcoma (avoid in bone metastases or a history of skeletal malignancies).
Forteo transiently increases serum calcium (hypercalcemia risk is addressed in labeling), which may predispose patients to digitalis toxicity.
5.5 Risk of Digoxin Toxicity (hypercalcemia may predispose; FORTEO transiently increases serum calcium).
Forteo use is limited in duration: use for more than 2 years during a patient's lifetime should only be considered if the patient remains/returns to high risk for fracture.
2.3 Recommended Treatment Duration.
Unsupported Statements
Forteo can be used after Prolia (denosumab) treatment.
Provided Forteo label text does not include denosumab/Prolia transition guidance.
Stopping Prolia abruptly can trigger rapid vertebral fractures due to a rebound effect.
Provided label text for Forteo contains no Prolia rebound fracture information.
Guidelines recommend bridging with an anabolic agent like Forteo before fully discontinuing Prolia.
No guideline/bridging recommendations involving Prolia are present in the provided Forteo label text.
Prolia suppresses bone resorption.
Not present in the provided Forteo label text (and no Prolia description is included).
The risk of fracture peaks 12-24 months after the last Prolia dose.
Not present in the provided Forteo label text.
Patients transitioning from denosumab to teriparatide maintained or improved BMD at the spine and hip.
No denosumab-to-teriparatide comparative effectiveness statements are present in the provided Forteo label text.
Transitioning from denosumab to teriparatide preserved gains compared with switching to bisphosphonates.
No denosumab comparator study claims are present in the provided Forteo label text.
An overlap period involves continuing Prolia for 1-2 doses while starting Forteo daily injections, then tapering off Prolia.
No Prolia overlap/tapering protocol is present in the provided Forteo label text.
Forteo is limited to 2 years lifetime use due to osteosarcoma risk in animal studies.
Label states >2 years may be considered only if high fracture risk persists; it does not state a strict 'limited to 2 years lifetime use' wording.
Serum CTX (a resorption marker) should be checked during monitoring after switching to Forteo.
No CTX/resorption-marker monitoring recommendation is present in the provided Forteo label text.
Calcium levels should be monitored when using Forteo.
The provided label excerpts discuss hypercalcemia/digitalis toxicity but do not provide a monitoring instruction for calcium levels.
Forteo can cause hypercalcemia and patients should be monitored for it.
Label excerpts provided mention hypercalcemia and digitalis toxicity consideration but do not explicitly instruct monitoring for hypercalcemia.
Endocrinology societies endorse using Forteo as a bridge for high-risk patients after prolonged Prolia use (e.g., osteoporosis after 3+ years of Prolia).
No Prolia/bridging society endorsements are present in the provided Forteo label text.
Up to 70% of patients lose prior BMD gains after stopping Prolia without Forteo.
No Prolia discontinuation/BMD loss statistics are present in the provided Forteo label text.
Stopping Prolia without Forteo is associated with 10-20% developing new vertebral fractures within a year.
No Prolia discontinuation vertebral fracture rate statistics are present in the provided Forteo label text.
The risk of denosumab holiday vertebral fractures is higher in patients with prior fractures.
No denosumab holiday risk stratification is present in the provided Forteo label text.
Patients with a history of hypercalcemia cannot use Forteo.
The provided label contraindications/avoid list does not state 'history of hypercalcemia' as a contraindication/avoidance criterion in the supplied text.
Forteo requires daily injections.
Forteo is once daily per label, but the claim wording 'requires daily injections' is not directly stated as such in the provided administration section (though it implies once-daily dosing). This is treated as unsupported because it adds a more absolute requirement phrasing beyond the label excerpt.
Forteo is described as the best option for preventing rebound and building new bone after Prolia.
No Prolia rebound prevention comparison is present in the provided Forteo label text.
Forteo is limited by a 2-year use limit.
Label allows consideration of use >2 years only if high risk persists; it is not presented as an absolute '2-year use limit' in the provided text.
Forteo is described as more costlier (~$2,500/month).
No cost information is present in the provided Forteo label text.
Forteo has U.S. patents expiring in 2025-2026.
No patent information is present in the provided Forteo label text.
There is no direct Prolia interaction warning in Forteo labeling.
The provided Forteo label excerpts do not allow assessing whether there is or is not a Prolia interaction warning.
FDA notes transition risks when changing from Prolia (denosumab).
Provided Forteo label excerpts do not include FDA notes on Prolia transitions.
Forteo is made by Eli Lilly.
No manufacturer/company information is included in the provided label text excerpts.
Contradictions
Low
AI Statement
Forteo is limited to 2 years lifetime use due to osteosarcoma risk in animal studies.
Label Reference
2.3 Recommended Treatment Duration (Use of FORTEO for more than 2 years during a patient's lifetime should only be considered if a patient remains at or has returned to having a high risk for fracture).
Low
AI Statement
Forteo is limited by a 2-year use limit.
Label Reference
2.3 Recommended Treatment Duration (more than 2 years may be considered if high risk persists/returns).
Low
AI Statement
Patients with a history of hypercalcemia cannot use Forteo.
Label Reference
4 CONTRAINDICATIONS (only hypersensitivity is listed in the provided text) and 5.1 Osteosarcoma avoid list; the provided text does not state hypercalcemia history as an contraindication/avoid criterion.
Important Omissions
Contraindications are limited to hypersensitivity to teriparatide or excipients (in the provided contraindications section); the AI set includes other absolute 'cannot use' statements (e.g., hypercalcemia history) without label support.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Several claims involve Prolia transition/rebound fracture guidance and specific monitoring protocols not supported by the provided Forteo label text. Additionally, duration-limit wording is more absolute than the label supports, and at least one 'cannot use' criterion (hypercalcemia history) is not supported by the provided contraindications/avoid criteria.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Majority of claims are not supported by the provided Forteo label text, especially all Prolia/denosumab transition and fracture-rebound timing statements.
Suggested Improvement
Remove or revise Prolia-related bridge/overlap, rebound fracture timing/rates, and BMD comparative transition claims unless supported by the provided label text. Align duration language to 'consider >2 years only if still/returned to high fracture risk' and ensure any 'cannot use' statements match the label's contraindications/avoid list provided.